However, achievement of molecular response targets, including BCR-ABL1 transcript levels below the limit of detection, does not necessarily correspond to complete CML remission; thus, CCyR remains the key response outcome in clinical trial and clinical practice settings. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.